Objective: To study the clinical efficacy of PEG-Interferon alpha-2a combined with ribavirin in eldly chronic hepatitis.
Methods: Forty patients with chronic hepatitis C were divided into treatment group and comparative group. The twenty eldly patients of treatment group receive peg-interferon alpha-2a 135-180 microg subcutaneous injection every week combined with ribavirin 600-1000 mg/d for 48 weeks, and twenty adult patients of control group receive peg-interferon 135-180 microg subcutaneous injection every week combined with ribavirin 800-1200 mg/d for 48 weeks. The rapid virological response (RVR) rate, early virological response (EVR) rate, end of treatment virological response (ETVR) rate, sustained virological response (SVR) rate, nonresponder rate, relapse rate and the side reaction was assessed, then to compare the differences between the two groups.
Results: The RVR rate, EVR rate, ETVR rate, SVR rate, nonresponder rate, relapse rate was 60%, 70%, 75%, 60%, 10%, 10% respectively, accordingly the rate in control group was 75%, 80%, 85%, 75%, 5%, 10%. The difference between the two group were not statistically significant (P > 0.05). Compared with the control group, the rate of neutropenia was higher in treatment group (P < 0.05). There was no difference between the two groups in influenza-like side effect, anemia, thrombocytopenia and gastrointestinal side reaction.
Conclusions: The eldly patients with Chronic Hepatitis C using general dose peg-IFNalpha-2a combined with lower dose ribavirin can still obtain the similar efficiency and excellent tolerance when the basic diseases such as hypertension, diabetes and side effects were treated successfully.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.
Cureus
December 2024
Internal Medicine, Dera Ghazi Khan Medical College, Dera Ghazi Khan, PAK.
This systematic review evaluates the outcomes of direct-acting antivirals (DAAs) compared to interferon-based therapies in patients with chronic hepatitis C infection. DAAs consistently demonstrate higher sustained virologic response (SVR) rates and better safety profiles across various patient populations, including those with cirrhosis and treatment-experienced individuals. The studies included highlight the superior efficacy of DAAs, with fewer adverse events such as anemia and fatigue, making them more tolerable and suitable for long-term treatment.
View Article and Find Full Text PDFS6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.
Front Immunol
January 2025
RNAimmune, Inc., Germantown, MD, United States.
Background: The unrelenting emergence of SARS-CoV-2 variants has significantly challenged the efficacy of existing COVID-19 vaccines. Enhancing the stability and immunogenicity of the spike protein is critical for improving vaccine performance and addressing variant-driven immune evasion.
Methods: We developed an mRNA-based vaccine, RV-1730, encoding the Delta variant spike protein with the S6P mutation to enhance stability and immunogenicity.
Exploring the therapeutic potential of acorn extract in papillomavirus-induced lesions.
Vet World
November 2024
Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
Background And Aim: Papillomaviruses (PVs) infections have been documented in numerous animal species across different regions worldwide. They often exert significant impacts on animal health and livestock production. Scientists have studied natural products for over half a century due to their diverse chemical composition, acknowledging their value in fighting cancer.
View Article and Find Full Text PDFReal-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan.
Kaohsiung J Med Sci
January 2025
Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
An 8-week regimen of glecaprevir/pibrentasvir is recommended for treatment-naïve patients with chronic hepatitis C (CHC). In alignment with the Taiwanese government's objective to eliminate hepatitis C by 2025, this study aimed to provide real-world evidence on the use of this regimen in treatment-naïve patients with chronic kidney disease (CKD) by using data from the Taiwan Association for the Study of the Liver HCV Registry (TACR). CKD was defined by an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.
View Article and Find Full Text PDFActivation of Evolutionarily Young Endogenous Retroviruses Is Implicated in COVID-19 Immunopathology.
Genes Cells
January 2025
Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Aichi, Japan.
The dysfunction of the innate immune system is well-described as a clinical characteristic of COVID-19. While several groups have reported human endogenous retroviruses (ERVs) as enhancing factors of immune reactivity, characterization of the COVID-19-specific ERVs has not yet been sufficiently conducted. Here, we revealed the transcriptome profile of more than 500 ERV subfamilies and innate immune response genes in eight different cohorts of platelet, peripheral blood mononuclear cells (PBMCs), lung, frontal cortex of brain, ventral midbrain, pooled human umbilical vein endothelial cells (pHUVECs), placenta, and cardiac microvascular endothelial cells (HCMEC) from COVID-19 patients (total; n = 124) and normal samples (total; n = 53) using publicly available datasets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!